A comprehensive view of Vertex Pharmaceuticals Inc.. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

The top women CEOs in America

Vertex licenses Maxcyte’s ExPERT cell engineering platform to develop experimental gene-edited therapy exa-cel, previously known at CXT001; Maxcyte to receive undisclosed licensing fee, program-related revenue

Vertex to merge with biotechnology company ViaCyte for US$320M, with ViaCyte to become wholly-owned subsidiary of Vertex upon completion of deal; ViaCyte developing novel stem cell therapies as possible cure for type 1 diabetes

FDA lifts clinical hold on Phase1/2 study of Vertex Pharma's stem cell-derived VX-880 injectable therapy to treat type 1 diabetes; trial reopening for screening, enrollment, dosing at sites in US

Vertex reports Q1 GAAP net income up 17% from a year ago to US$762.0M, revenues up 22% year-over-year to US$2.1B, driven by Trikafta cystic fibrosis drug, with Health Canada approving drug for children 6-to-11 years of age; US sales up 9% year-over-year

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count